Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07085611
Recruiting Not applicable

Neutralizing Power of Serum Antibodies - 2

NCT07085611 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier Régional d'Orléans
Phase
Not applicable
Started
2025-08-22
Last updated
2025-12-19

Condition(s) studied

COVID-19SARS-CoV-2 ViraemiaMonkey PoxVaccinationSerumMucosal Immunity

Investigational drug(s) / intervention(s)

Sample collection (blood and optional nasal swab)

Sample collection (blood and optional nasal swab): Venous blood collection (2 tubes of 6 mL) and optional nasal swab at each visit. Aliquots analyzed for neutralizing activity against SARS-CoV-2 and MPXV using validated assays at Institut Pasteur

Study summary

Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies. This neutralizing power is recognized as a correlate of protection against a new infection. This study aims to describe the neutralizing power of serum and nasal antibodies over time, in relation to SARS-CoV-2 and MPXV vaccines or treatments received.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults (≥18 years) * Patients receiving or scheduled to receive anti-SARS-CoV-2 and/or anti-MPXV vaccines or monoclonal antibodies * Patients have provided written informed consent Exclusion Criteria: * Persons under guardianship or curatorship * Persons under legal protection, * Persons persons deprived of liberty * Persons not affiliated to a social security scheme * Pregnant or breastfeeding women

Primary outcome measure(s)

  • Serum neutralizing antibody evolution (anti-SARS-CoV-2 and anti-MPXV) over time — Up to 60 months
    S-Fuse and S-Flow tests performed on collected serum samples at each visit

Trial sites (1)

FacilityCityRegionStatus
CHU Orléans Orléans France Recruiting

More Centre Hospitalier Régional d'Orléans trials in France

Study of Tolerance to the Application of Cold Plasma in the Treatment of Chronic Wounds Recruiting
Cohort Study on Medical Students' Mental Health Recruiting
Personalised Education Versus Usual Physiotherapy for Acute Rotator Cuff-Related Shoulder Pain Starting soon
Study of Autophagy and the Effects of GALIG Gene Products in HIV-1 Infected Patients Who Are Under Antiretroviral Therapy Since Primary-infection, Chronic Phase, or Never Treated. Recruiting
Assessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic ESKD Patients. Recruiting

Other trials for the same condition

Prevalence and Clinical Significance of Anti-annexin A2 Antibodies in COVID-19 Infection Recruiting
Pulmonary Function in Patients Recovering From COVID19 Infection : a Pilot Study Active, not recruiting
Evaluation of Concordance Between Exhaled Air Test (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2 Recruiting
Clinical and Biological Aspects of the MONKEYPOX Disease Recruiting
Thrombo Embolic Events in Hospitalized Patients With Covid-19 Serious Acute Pneumopathy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07085611 on ClinicalTrials.gov ↗ ← All trials in France